LIVINGLIVING
By partnering with Diabeloop, Roche steps into the field of automated
insulin delivery (AID), representing a milestone in Roche's strategy of
integrated Personalised Diabetes Management (iPDM).
ROCHE & DIABELOOP
Roche has teamed up with Frenchbased closed loop app Diabeloop in
order to advance the management of
insulin pump therapy. The partnership
will create new opportunities to lower the
burden for people with diabetes in daily
therapy management and to improve
therapy outcomes - i.e. better control. By
partnering with Diabeloop, Roche steps
into the field of automated insulin delivery
(AID), representing a milestone in Roche's
strategy of integrated Personalised
Diabetes Management (iPDM).
By building on its own strengths
and expanding its offering through the
partnership with Diabeloop, Roche is
embracing its vision to bring innovation
to people with diabetes helping them to
experience true relief. Marcel Gmuender,
Global Head of Roche Diabetes Care,
commented on the news saying,
"Everybody at Roche Diabetes Care
is excited about the new partnership
with Diabeloop. The technology of
Diabeloop, based on a self-learning
algorithm, is unique. We are convinced
that the potential of the hybrid closedloop systems will contribute to a more
efficient and personalised approach of
diabetes management. For more than
three decades, we have been committed
to supporting people with diabetes
with a range of different insulin pump
technologies. Throughout the years, we
have always aimed to give people with
diabetes choice, so that they can select
the best therapy solutions to suit their
needs. Together with Diabeloop, we are
again expanding the choice of options
available to people with diabetes, by
embarking on our journey of automated
insulin delivery."
Erik Huneker, Diabeloop founder and
co-CEO has welcomed the arrangement
saying, "Reliable insulin delivery is a critical
component in Diabeloop's hybrid closedloop systems embedding therapeutic
artificial intelligence. The accuracy and
reliability of Roche's insulin pump portfolio
perfectly fits our vision to personalise
therapy to the physiology and lifestyle
of people with diabetes, helping them to
spend less time managing diabetes while
improving time in range."
www.diabeloop.com
KIT
REPORT